Skip to main content

Advertisement

Table 1 Baseline demographic and clinical data

From: Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study

  Full cohort SD ATII SD Placebo SD P-value1
Age, years 62.85 15.81 68.40 17.46 57.30 12.44 0.12
Male, number 15 NA 6 NA 9 NA 0.30
Race, number        
Caucasian 9 NA 6 NA 3 NA 0.37
Black 8 NA 3 NA 5 NA 0.65
Other 3 NA 1 NA 2 NA 1.00
Severity of illness   NA   NA   NA  
Baseline SOFA score 15.90 2.97 14.9 2.81 16.90 2.92 0.14
APACHE score 30.60 8.86 27.2 9.67 34.00 6.83 0.09
Past medical history, number        
IHD 2 NA 1 NA 1 NA 1.00
CHF 2 NA 2 NA 0 NA 0.47
COPD 2 NA 2 NA 0 NA 0.47
DM 7 NA 4 NA 3 NA 1.00
CKD 7 NA 3 NA 4 NA 1.00
HD 1 NA 0 NA 1 NA 1.00
Liver disease 9 NA 5 NA 4 NA 1.00
Cancer 6 NA 1 NA 5 NA 0.14
IS 6 NA 1 NA 5 NA 0.14
Steroids 3 NA 1 NA 2 NA 1.00
Hypertension 9 NA 4 NA 5 NA 1.00
CVA 5 NA 4 NA 1 NA 0.30
AKI 17 NA 9 NA 8 NA 1.00
Laboratory measurements mean        
White blood cells 17.38 NA 19.0 16.0 15.72 12.3 0.61
Hgb 9.45 NA 9.16 2.14 9.73 2.45 0.59
Creatinine 2.33 NA 1.89 1.03 2.76 1.34 0.12
pH 7.33 NA 7.34 0.11 7.32 0.12 0.63
Lactate 5.83 NA 4.59 3.11 7.06 5.16 0.21
Baseline vasopressor doses2        
Norepinephrine 25.05 17.03 19.80 11.67 30.30 20.37 0.18
Vasopressin 0.04 0.02 0.03 0.02 0.05 0.02 0.10
  1. Results are presented as mean and SD or number. 1P-values for continuous variables calculated using Student's t-test. P-values for discrete variables calculated using Fisher exact test. 2One patient in the placebo group received phenylephrine infusion prior to initiation of angiotensin II (ATII) versus no patients in the ATII group. One patient in the placebo group received epinephrine versus no patients in the ATII group. SOFA, sequential organ function assessment; APACHE, acute physiology and chronic health evaluation II; IHD, ischemic heart disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; CKD, chronic kidney disease; HD, hemodialysis; IS, immunocompromised state; CVA, cerebrovascular accident; AKI, acute kidney injury; Hgb, hemoglobin; NA, to represent not analysed, not applicable, or not available.